Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The FDA delays full approval for Novavax's COVID-19 vaccine, citing the need for additional data. Read more here.

The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1.

Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration’s top vaccine official has been pushed out. Shares in some larger drugmakers, ...

Novavax (NasdaqGS:NVAX) recently experienced a significant decline of 21% over the past week, coinciding with leadership changes, including the retirement of longtime Chairman James Young and the ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

Shares of Novavax Inc. NVAX slipped 8.43% to $6.41 Monday, on what proved to be an all-around mixed trading session for the ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...